BTIG Maintains Buy on Solventum, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 69.8%

Neg 0% Neu 0% Pos 69.8%

BTIG analyst Ryan Zimmerman maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $91 to $95.

Comments

No comments yet. Be the first!